LMNL News and Press, Liminal Biosciences Inc From 05/28/21

Liminal BioSciences (LMNL) announces that it has decided to stop its plans to move fezagepras into a Phase II study in Idiopathic Pulmonary Fibrosis and a phase Ia/IIb study in Hypertriglyceridemia, following interim pharmacokinetic ("PK") results.Shares down nearly 12% post market....

Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras Canada NewsWire LAVAL, QC and CAMBRIDGE, England , May 28, 2021 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a c...

Liminal BioSciences (LMNL) announces that it has closed the previously announced divestment of its 2 plasma collection centers, Prometic Plasma Resources and Prometic Plasma Resources ((USA)) to Kedrion S.p.A.Have also entered into an option agreement granting Kedrion the right to acquire the...

Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement with Kedrion Canada NewsWire LAVAL, QC and CAMBRIDGE, England , May 21, 2021 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal Bi...

Liminal Biosciences shares skyrocketed last August as the FDA handed an Emergency Use Authorization to convalescent plasma treatments to treat hospitalized COVID patients. The upside was short lived, however, as studies showed that the treatment did not improve patients' conditions. L...

Liminal BioSciences (LMNL): Q1 Net Loss of $20.9MCash and cash equivalents of $21.6MPress Release For further details see: Liminal BioSciences reports Q1 results

Liminal BioSciences Reports First Quarter 2021 Financial Results PR Newswire Updated Business Strategy Focused on Small Molecule Therapeutics Kedrion to acquire, for a total of USD 17M , 2 plasma collection centers and an option to acquire the remaining p...

Liminal BioSciences (LMNL) has signed a binding share purchase agreement for the sale of its plasma collection centers operated in Winnipeg, Manitoba and Amherst, New York, through its subsidiaries, Prometic Plasma Resources, and Prometic Plasma Resources ((USA)).The compa...

Liminal BioSciences Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutics Business PR Newswire Kedrion to acquire, for a total of USD 17M , 2 plasma collection centers and an option to acquire the remaining plasma-deri...

Liminal BioSciences, Inc. (LMNL) Q4 2020 Earnings Conference Call March 25, 2021, 08:30 ET Company Participants Shrinal Inamdar - Investor Relations and Communications Manager Bruce Pritchard - CEO Patrick Sartore - President Murielle Lortie - CFO Conference Call Participants Yasmeen Rahimi -...